A Phase 3 interventional study of Placebo for Upadacitinib and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 180 sites in 25 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 912 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 3rd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2018, is one of 12 in phase 3, and was the 2nd registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit.
Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled in the overall study (main study + adolescent sub-study).
Randomization for the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD 3] vs. severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).
At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [yes/no], geographic region [US/Puerto Rico/Canada, China [Mainland], Japan, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).
Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose.
Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary.
The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
Following the interim analysis, significant noncompliance was identified at a clinical site. As a result, all data from the site, including data from 10 adolescent participants, has been excluded from the final analysis of the outcome measures as appropriate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active moderate to severe AD defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Drug: Placebo for Upadacitinib · Drug: Upadacitinib
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
Drug: Upadacitinib
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
Drug: Upadacitinib
Tablets taken orally once a day
Tablets taken orally once a day
Also known as: ABT-494, RINVOQ™
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 2
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.
Time frame: Baseline and Day 2
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.
Time frame: Baseline and Day 3
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.
Time frame: From first dose of study drug to Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16
The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
Time frame: Baseline and Week 16
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
Time frame: Week 16
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 2
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Day 2
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Day 3
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.
Time frame: From first dose of study drug to Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16
The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
Time frame: Baseline and Week 16
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
Time frame: Baseline and Week 16
Participants were enrolled at 151 study sites in 24 countries across Europe, North and South America, Oceania, and the Asia-Pacific region. The study included a 16-week double-blind treatment period followed by a blinded extension period up to Week 260, and a 30-day follow-up visit. The first 810 adults and adolescents enrolled constituted the Main Study; additional adolescents were enrolled in the Adolescent Substudy to ensure enrollment of a total of 180 adolescent participants overall.
| Milestone | Adults: Double-blind Period - Placebo | Adults: Double-blind Period - Upadacitinib 15 mg QD | Adults: Double-blind Period - Upadacitinib 30 mg QD | Adolescents: Double-blind Period - Placebo | Adolescents: Double-blind Period - Upadacitinib 15 mg QD | Adolescents: Double-blind Period - Upadacitinib 30 mg QD | Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adults: Blinded Extension Period - Upadacitinib 15 mg | Adults: Blinded Extension Period - Upadacitinib 30 mg | Adolescents: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adolescents: Blinded Extension Period - Upadacitinib 15 mg | Adolescents: Blinded Extension Period - Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 241 | 239 | 243 | 61 | 64 | 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received study drug in double-blind period | 241 | 239 | 243 | 61 | 64 | 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Updated itt adolescent (itt a) population | 0 | 0 | 0 | 58 | 63 | 58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 209 | 231 | 231 | 57 | 64 | 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 32 | 8 | 12 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 18 | 2 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 9 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Adults: Double-blind Period - Placebo | Adults: Double-blind Period - Upadacitinib 15 mg QD | Adults: Double-blind Period - Upadacitinib 30 mg QD | Adolescents: Double-blind Period - Placebo | Adolescents: Double-blind Period - Upadacitinib 15 mg QD | Adolescents: Double-blind Period - Upadacitinib 30 mg QD | Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adults: Blinded Extension Period - Upadacitinib 15 mg | Adults: Blinded Extension Period - Upadacitinib 30 mg | Adolescents: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adolescents: Blinded Extension Period - Upadacitinib 15 mg | Adolescents: Blinded Extension Period - Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 105 | 231 | 231 | 30 | 27 | 64 | 64 |
| Received treatment in the be period | 0 | 0 | 0 | 0 | 0 | 0 | 102 | 105 | 231 | 228 | 30 | 27 | 64 | 64 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 62 | 119 | 120 | 22 | 14 | 37 | 41 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 43 | 112 | 111 | 8 | 13 | 27 | 23 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 17 | 22 | 0 | 2 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 28 | 57 | 59 | 5 | 7 | 15 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 17 | 14 | 1 | 3 | 6 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 | 21 | 16 | 2 | 1 | 2 | 4 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | 16.3 (12.0 to 20.7) | 69.6 (64.2 to 75.0) | 79.7 (75.0 to 84.4) |
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 | 8.4 (5.2 to 11.7) | 48.1 (42.3 to 54.0) | 62.0 (56.4 to 67.7) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16 | 11.8 (7.9 to 15.6) | 52.2 (46.3 to 58.1) | 60.0 (54.3 to 65.7) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16 | 8.1 (4.9 to 11.3) | 53.1 (47.2 to 58.9) | 65.8 (60.2 to 71.3) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 | 4.4 (2.0 to 6.9) | 51.5 (45.5 to 57.4) | 66.8 (61.3 to 72.3) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2 | 3.6 (1.4 to 5.7) | 38.1 (32.4 to 43.8) | 47.4 (41.6 to 53.2) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 | 0.4 (0.0 to 1.1) | 15.0 (10.7 to 19.2) | 19.6 (15.0 to 24.3) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2 | 3.7 (1.5 to 6.0) | 10.5 (6.9 to 14.2) | 11.8 (8.0 to 15.6) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3 | 3.3 (1.2 to 5.5) | 16.4 (12.0 to 20.7) | 21.1 (16.4 to 25.9) |
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period | 25.2 (20.0 to 30.3) | 1.1 (0.0 to 2.3) | 0.0 (NA to NA) |
The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16 | 13.2 (8.7 to 17.7) | 55.0 (48.4 to 61.6) | 66.1 (59.8 to 72.3) |
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16 | 15.0 (10.4 to 19.6) | 53.6 (47.2 to 59.9) | 63.5 (57.5 to 69.4) |
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16 | 15.0 (10.4 to 19.7) | 53.6 (47.2 to 60.1) | 67.9 (62.1 to 73.7) |
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16 | 19.8 (14.4 to 25.2) | 62.6 (56.3 to 68.9) | 72.6 (66.7 to 78.4) |
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16 | 20.3 (14.7 to 25.9) | 65.0 (58.5 to 71.6) | 73.2 (67.1 to 79.2) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16 | 1.8 (0.2 to 3.3) | 16.7 (12.4 to 21.1) | 27.0 (21.9 to 32.2) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
| percent change | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16 | -26.06 (-36.66 to -15.46) | -62.79 (-71.60 to -53.99) | -72.04 (-80.69 to -63.39) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percent Change From Baseline in EASI Score at Week 16 | -40.71 (-45.18 to -36.23) | -80.24 (-83.99 to -76.49) | -87.74 (-91.42 to -84.06) |
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16 | 22.8 (17.8 to 27.8) | 75.0 (69.9 to 80.1) | 81.4 (76.9 to 86.0) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 | 29.0 (23.3 to 34.7) | 75.4 (70.1 to 80.8) | 82.0 (77.3 to 86.7) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
| percent change | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16 | -32.68 (-37.26 to -28.11) | -65.71 (-69.20 to -62.23) | -73.07 (-76.47 to -69.68) |
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16 | 14.3 (8.2 to 20.4) | 45.5 (37.4 to 53.6) | 49.2 (41.0 to 57.4) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
| percentage of participants | Placebo | Upadacitinib 15 mg QD | Upadacitinib 30 mg QD |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16 | 4.4 (1.9 to 7.0) | 30.3 (24.7 to 35.9) | 41.5 (35.5 to 47.4) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16 | 12.1 (3.7 to 20.5) | 74.6 (63.9 to 85.4) | 84.5 (75.2 to 93.8) |
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 | 6.9 (0.4 to 13.4) | 46.0 (33.7 to 58.3) | 70.7 (59.0 to 82.4) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16 | 10.5 (2.6 to 18.5) | 49.2 (36.6 to 61.7) | 58.9 (46.0 to 71.8) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16 | 3.4 (0.0 to 8.1) | 47.6 (35.3 to 60.0) | 74.1 (62.9 to 85.4) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 | 3.5 (0.0 to 8.3) | 49.2 (36.6 to 61.7) | 64.3 (51.7 to 76.8) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2 | 3.4 (0.0 to 8.1) | 39.7 (27.6 to 51.8) | 55.8 (42.9 to 68.7) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 | 0.0 (NA to NA) | 9.8 (2.4 to 17.3) | 23.2 (12.2 to 34.3) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2 | 1.8 (0.0 to 5.3) | 14.0 (5.0 to 23.1) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD |
|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3 | 5.4 (0.0 to 11.3) | 16.9 (7.4 to 26.5) |
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period | 23.2 (12.2 to 34.3) | 0.0 (NA to NA) | 0.0 (NA to NA) |
The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16 | 13.3 (3.4 to 23.3) | 47.9 (33.8 to 62.0) | 70.7 (56.8 to 84.7) |
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16 | 9.8 (0.7 to 18.8) | 43.4 (30.1 to 56.7) | 67.9 (55.4 to 80.5) |
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16 | 13.0 (3.3 to 22.8) | 51.0 (37.3 to 64.7) | 70.0 (57.3 to 82.7) |
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16 | 20.9 (8.8 to 33.1) | 60.9 (46.8 to 75.0) | 78.6 (66.2 to 91.0) |
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16 | 27.5 (13.7 to 41.3) | 57.1 (42.2 to 72.1) | 81.6 (69.3 to 93.9) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16 | 0.0 (NA to NA) | 15.9 (6.8 to 24.9) | 34.5 (22.3 to 46.7) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
| percent change | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16 | -24.36 (-35.34 to -13.37) | -59.01 (-68.01 to -50.00) | -70.00 (-79.19 to -60.81) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percent Change From Baseline in EASI Score at Week 16 | -43.53 (-51.37 to -35.69) | -82.13 (-88.37 to -75.89) | -89.42 (-95.82 to -83.02) |
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16 | 27.3 (15.5 to 39.0) | 80.6 (70.8 to 90.5) | 87.9 (79.5 to 96.3) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16 | 33.3 (13.2 to 53.5) | 81.5 (66.8 to 96.1) | 79.3 (64.6 to 94.1) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
| percent change | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percent Change From Baseline in SCORAD Score at Week 16 | -30.90 (-39.39 to -22.40) | -65.42 (-71.81 to -59.03) | -76.35 (-82.80 to -69.90) |
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16 | 3.8 (0.0 to 11.2) | 48.6 (32.0 to 65.1) | 55.6 (36.8 to 74.3) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.
| percentage of participants | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16 | 4.8 (0.0 to 13.9) | 22.2 (6.5 to 37.9) | 30.0 (13.6 to 46.4) |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time followed ranged from 128.5 days to 133.0 days for the double-blind period and from 1688.0 days to 1711.5 days for the blinded extension period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults: Double-blind Period - Placebo | 0/241 (0%) | 9/241 (3.7%) | 111/241 (46.1%) |
| Adults: Double-blind Period - Upadacitinib 15 mg QD | 0/239 (0%) | 5/239 (2.1%) | 104/239 (43.5%) |
| Adults: Double-blind Period - Upadacitinib 30 mg QD | 0/243 (0%) | 8/243 (3.3%) | 142/243 (58.4%) |
| Adolescents: Double-blind Period - Placebo | 0/61 (0%) | 1/61 (1.6%) | 18/61 (29.5%) |
| Adolescents: Double-blind Period - Upadacitinib 15 mg QD | 0/64 (0%) | 2/64 (3.1%) | 33/64 (51.6%) |
| Adolescents: Double-blind Period - Upadacitinib 30 mg QD | 0/64 (0%) | 0/64 (0%) | 32/64 (50%) |
| Adults: Blinded Extension Period - Upadacitinib 15 mg | 2/231 (0.9%) | 33/231 (14.3%) | 160/231 (69.3%) |
| Adults: Blinded Extension Period - Upadacitinib 30 mg | 2/228 (0.9%) | 42/228 (18.4%) | 189/228 (82.9%) |
| Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg | 0/102 (0%) | 15/102 (14.7%) | 78/102 (76.5%) |
| Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg | 1/105 (1%) | 21/105 (20%) | 89/105 (84.8%) |
| Adolescents: Blinded Extension Period - Upadacitinib 15 mg QD | 0/64 (0%) | 8/64 (12.5%) | 44/64 (68.8%) |
| Adolescents: Blinded Extension Period - Upadacitinib 30 mg QD | 0/64 (0%) | 7/64 (10.9%) | 48/64 (75%) |
| Adolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mg | 0/30 (0%) | 1/30 (3.3%) | 20/30 (66.7%) |
| Adolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg | 0/27 (0%) | 6/27 (22.2%) | 22/27 (81.5%) |
| Event | Adults: Double-blind Period - Placebo | Adults: Double-blind Period - Upadacitinib 15 mg QD | Adults: Double-blind Period - Upadacitinib 30 mg QD | Adolescents: Double-blind Period - Placebo | Adolescents: Double-blind Period - Upadacitinib 15 mg QD | Adolescents: Double-blind Period - Upadacitinib 30 mg QD | Adults: Blinded Extension Period - Upadacitinib 15 mg | Adults: Blinded Extension Period - Upadacitinib 30 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adolescents: Blinded Extension Period - Upadacitinib 15 mg QD | Adolescents: Blinded Extension Period - Upadacitinib 30 mg QD | Adolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mg | Adolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TACHYCARDIACardiac disorders | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 0/228 | 0/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| APPENDICITISInfections and infestations | 0/241 | 1/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 1/228 | 1/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| OSTEOMYELITISInfections and infestations | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 1/228 | 0/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| PYELONEPHRITISInfections and infestations | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 0/228 | 0/102 | 1/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| STAPHYLOCOCCAL SEPSISInfections and infestations | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 1/231 | 1/228 | 0/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| RHABDOMYOLYSISMusculoskeletal and connective tissue disorders | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 0/228 | 0/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| DEPRESSIONPsychiatric disorders | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 0/228 | 1/102 | 0/105 | 0/64 | 0/64 | 0/30 | 1/27 |
| PERITONSILLAR ABSCESSInfections and infestations | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 0/231 | 0/228 | 0/102 | 0/105 | 0/64 | 0/64 | 1/30 | 0/27 |
| ECZEMA HERPETICUMInfections and infestations | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 1/231 | 0/228 | 0/102 | 3/105 | 0/64 | 0/64 | 0/30 | 0/27 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 0/241 | 0/239 | 0/243 | 0/61 | 0/64 | 0/64 | 1/231 | 1/228 | 2/102 | 0/105 | 0/64 | 0/64 | 0/30 | 0/27 |
| Event | Adults: Double-blind Period - Placebo | Adults: Double-blind Period - Upadacitinib 15 mg QD | Adults: Double-blind Period - Upadacitinib 30 mg QD | Adolescents: Double-blind Period - Placebo | Adolescents: Double-blind Period - Upadacitinib 15 mg QD | Adolescents: Double-blind Period - Upadacitinib 30 mg QD | Adults: Blinded Extension Period - Upadacitinib 15 mg | Adults: Blinded Extension Period - Upadacitinib 30 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg | Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg | Adolescents: Blinded Extension Period - Upadacitinib 15 mg QD | Adolescents: Blinded Extension Period - Upadacitinib 30 mg QD | Adolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mg | Adolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/241 | 0/239 | 1/243 | 0/61 | 1/64 | 0/64 | 66/231 | 80/228 | 39/102 | 40/105 | 16/64 | 23/64 | 6/30 | 6/27 |
| ACNESkin and subcutaneous tissue disorders | 7/241 | 13/239 | 40/243 | 1/61 | 9/64 | 10/64 | 25/231 | 43/228 | 14/102 | 24/105 | 1/64 | 18/64 | 5/30 | 10/27 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 17/241 | 23/239 | 31/243 | 5/61 | 5/64 | 8/64 | 35/231 | 35/228 | 19/102 | 14/105 | 14/64 | 18/64 | 5/30 | 9/27 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 20/241 | 9/239 | 5/243 | 2/61 | 2/64 | 1/64 | 37/231 | 41/228 | 19/102 | 10/105 | 8/64 | 6/64 | 4/30 | 8/27 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 4/241 | 12/239 | 11/243 | 2/61 | 5/64 | 5/64 | 19/231 | 35/228 | 4/102 | 18/105 | 8/64 | 9/64 | 5/30 | 6/27 |
| NASOPHARYNGITISInfections and infestations | 16/241 | 19/239 | 28/243 | 1/61 | 3/64 | 5/64 | 38/231 | 32/228 | 15/102 | 13/105 | 8/64 | 8/64 | 3/30 | 4/27 |
| HERPES ZOSTERInfections and infestations | 0/241 | 4/239 | 4/243 | 0/61 | 1/64 | 1/64 | 23/231 | 30/228 | 3/102 | 12/105 | 1/64 | 7/64 | 2/30 | 4/27 |
| IMPETIGOInfections and infestations | 6/241 | 3/239 | 2/243 | 0/61 | 1/64 | 1/64 | 11/231 | 12/228 | 2/102 | 4/105 | 5/64 | 8/64 | 2/30 | 2/27 |
| HORDEOLUMInfections and infestations | 1/241 | 0/239 | 5/243 | 0/61 | 1/64 | 0/64 | 2/231 | 10/228 | 3/102 | 2/105 | 0/64 | 1/64 | 0/30 | 3/27 |
| PHARYNGITISInfections and infestations | 0/241 | 1/239 | 1/243 | 0/61 | 1/64 | 1/64 | 6/231 | 2/228 | 2/102 | 1/105 | 1/64 | 3/64 | 2/30 | 3/27 |
All randomized participants
| Age, Continuous(years) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 37.6 ± 14.44 | 37.3 ± 14.80 | 36.7 ± 15.12 | 15.1 ± 1.70 | 15.5 ± 1.99 | 15.7 ± 1.63 | 32.7 ± 15.87 |
| Age, Customized(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| 12 - 14 years | 0 | 0 | 0 | 23 | 22 | 15 | 60 |
| 15 - 17 years | 0 | 0 | 0 | 38 | 42 | 49 | 129 |
| 18 - < 40 years | 145 | 143 | 154 | 0 | 0 | 0 | 442 |
| 40 - < 65 years | 85 | 83 | 74 | 0 | 0 | 0 | 242 |
| ≥ 65 years | 11 | 13 | 15 | 0 | 0 | 0 | 39 |
| Sex: Female, Male(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 114 | 103 | 110 | 33 | 34 | 36 | 430 |
| Male | 127 | 136 | 133 | 28 | 30 | 28 | 482 |
| Ethnicity (NIH/OMB)(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 30 | 27 | 34 | 10 | 13 | 19 | 133 |
| Not Hispanic or Latino | 211 | 212 | 209 | 51 | 51 | 45 | 779 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| Asian | 62 | 57 | 61 | 10 | 12 | 10 | 212 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
| Black or African American | 16 | 20 | 7 | 6 | 6 | 0 | 55 |
| White | 157 | 153 | 163 | 41 | 45 | 50 | 609 |
| More than one race | 4 | 8 | 11 | 2 | 1 | 4 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Study Enrollment(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Main Study | 241 | 239 | 243 | 40 | 42 | 42 | 847 |
| Adolescent Substudy (not included in main study) | 0 | 0 | 0 | 21 | 22 | 22 | 65 |
| Geographic Region(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| US/Puerto Rico/Canada | 108 | 107 | 108 | 31 | 33 | 33 | 420 |
| Japan | 13 | 14 | 14 | 1 | 1 | 2 | 45 |
| China | 13 | 13 | 15 | 1 | 1 | 2 | 45 |
| Other | 107 | 105 | 106 | 28 | 29 | 27 | 402 |
| vIGA-AD(Participants) | Adults: Placebo | Adults: Upadacitinib 15 mg QD | Adults: Upadacitinib 30 mg QD | Adolescents: Placebo | Adolescents: Upadacitinib 15 mg QD | Adolescents: Upadacitinib 30 mg QD | Total |
|---|---|---|---|---|---|---|---|
| 3 (Moderate) | 132 | 130 | 129 | 35 | 35 | 37 | 498 |
| 4 (Severe) | 109 | 109 | 114 | 26 | 29 | 27 | 414 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 180 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Aug 2018 to primary completion in Jan 2021, 28 months.
Results were first posted in Feb 2022, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib